CVRx (CVRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors: Michael Dale, Kevin Hykes, and Joseph Slattery is proposed for shareholder approval.
Ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is up for vote.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Grant Thornton LLP is nominated for ratification as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CVRx
- Barostim therapy gains momentum with expanded access, strong evidence, and accelerating U.S. growth.CVRX
Goldman Sachs 47th Annual Global Healthcare Conference 202611 Jun 2026 - Barostim's clinical success and new coverage drive heart failure market expansion and access.CVRX
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Directors were elected, auditor ratified, and no stockholder questions were raised.CVRX
AGM 20261 Jun 2026 - Q1 2026 revenue rose 20% with strong U.S. growth, margin gains, and market expansion efforts.CVRX
Q1 202612 May 2026 - Annual meeting to elect directors, ratify auditor, and address governance and compensation.CVRX
Proxy filing20 Apr 2026 - 2025 revenue up 10%, margins improve, and 2026 outlook projects continued growth.CVRX
Q4 202512 Feb 2026 - Q2 revenue up 24% to $11.8M; net loss widens, full-year outlook raised.CVRX
Q2 20242 Feb 2026 - Barostim delivers breakthrough heart failure therapy, targeting a $2.2B U.S. market with strong results.CVRX
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Barostim targets a large unmet heart failure need with strong growth, evidence, and leadership focus.CVRX
The 44th Annual William Blair Growth Stock Conference1 Feb 2026